Search

Your search keyword '"Joharatnam-Hogan, Nalinie"' showing total 38 results
Start Over Author "Joharatnam-Hogan, Nalinie"
38 results on '"Joharatnam-Hogan, Nalinie"'

1. The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study

Author

Corianò, Matilde, Tommasi, Chiara, Dinh, Anh Thi Lan, Needham, Jazmine, Aziz, Hala, Joharatnam-Hogan, Nalinie, Cunningham, Niamh, Waterhouse, Jasmin, Sun, Mingze, Turkes, Fiona, Pellegrino, Benedetta, McGrath, Sophie, Okines, Alicia, Parton, Marina, Turner, Nicholas, Johnston, Stephen, Musolino, Antonino, Ring, Alistair, and Battisti, Nicolò Matteo Luca

Published
2024
Full Text
View/download PDF

2. Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial

Author

Joharatnam-Hogan, Nalinie, Hatem, Duaa, Cafferty, Fay H., Petrucci, Giovanna, Cameron, David A., Ring, Alistair, Kynaston, Howard G., Gilbert, Duncan C., Wilson, Richard H., Hubner, Richard A., Swinson, Daniel E. B., Cleary, Siobhan, Robbins, Alex, MacKenzie, Mairead, Scott-Brown, Martin W. G., Sothi, Sharmila, Dawson, Lesley K., Capaldi, Lisa M., Churn, Mark, Cunningham, David, Khoo, Vincent, Armstrong, Anne C., Ainsworth, Nicola L., Horan, Gail, Wheatley, Duncan A., Mullen, Russell, Lofts, Fiona J., Walther, Axel, Herbertson, Rebecca A., Eaton, John D., O’Callaghan, Ann, Eichholz, Andrew, Kagzi, Mohammed M., Patterson, Daniel M., Narahari, Krishna, Bradbury, Jennifer, Stokes, Zuzana, Rizvi, Azhar J., Walker, Georgina A., Kunene, Victoria L., Srihari, Narayanan, Gentry-Maharaj, Aleksandra, Meade, Angela, Patrono, Carlo, Rocca, Bianca, and Langley, Ruth E.

Published
2023
Full Text
View/download PDF

3. Personalising adjuvant therapy in common solid tumours using data from the Add-Aspirin trial

Author

Joharatnam-Hogan, Nalinie

Abstract

Background: Personalisation of medicine involves the categorisation of patients into biologically stratified groups enabling more tailored treatment for the individual. Using data from the Add-Aspirin trial, I aimed to improve trial outcomes and methodology by evaluating three different aspects of personalised approaches to cancer care. Through review of geriatric assessments (GA) embedded within the trial, I evaluated older participants in the trial as an example of patient-related personalisation. Secondly, through a collaboration with pharmacologists in Rome I explored differences in levels of platelet activation between participants with cancer and the effect of aspirin, using the in vivo marker urinary 11-dehydro-thromboxane B2 (TXB2) excretion - treatment-related personalisation. Finally I assessed the feasibility of a molecularly stratified adjuvant trial of immune checkpoint inhibition in colorectal cancers, as an example of tumour-related personalisation, by reviewing the extent and accuracy of mismatch repair (MMR) reporting across all UK sites. Results: Evaluation of GA results in 1905 participants over 65 years, using available data from October 2015 to 2020, demonstrated that patients aged 70 years and over were significantly less likely to proceed from the run-in period to randomised phase, and more likely to cease randomised trial treatment early compared to patients aged 65-69 years (p<0.05). A high rate of cognitive impairment (using the Montreal Cognitive Assessment) was observed in this otherwise fit population of older individuals. Enhanced platelet activation was identified at baseline between June 2018 and February 2020 in n=575 patients with a diagnosis of cancer (median urine TXB2 719 pg/mg creatinine), particularly in individuals with gastro-oesophageal and colorectal cancer (p < 0.001). Higher excretion rates of TXB2 were also found in patients with known stimuli of inflammation including BMI > 35 kg/m2, and elevated inflammatory markers. Low dose (100mg) aspirin inhibited thromboxane biosynthesis to levels expected in healthy people, with only a slight further reduction with a 3-fold higher aspirin dose. Evaluation of colorectal pathology forms from 1474 participants recruited between October 2015 and December 2019 exposed the national underutilisation of mismatch repair (MMR) testing. Thus, an adjuvant trial of immune checkpoint inhibitors in MMR deficient colorectal cancers is not feasible without an international effort or improvement in rates of testing. Furthermore, concerns were raised about the accuracy of more complex clinical trial data collection. Conclusion: Formalising personalisation, rather than clinical acumen alone, including the use of GA in older trial participants, biomarkers to evaluate pharmacodynamics, as well as molecular stratification factors, is required even with simple repurposed drugs such as aspirin.

Published
2022

4. REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers

Author

Merrick, Sophie, Nankivell, Matthew, Quartagno, Matteo, Clarke, Caroline S., Joharatnam-Hogan, Nalinie, Waddell, Tom, O'Carrigan, Brent, Seckl, Michael, Ghorani, Ehsan, Banks, Emma, Edmonds, Kim, Bray, George, Woodward, Rose, Bennett, Rachel, Badrock, Jonathan, Hudson, Will, Langley, Ruth E., Vasudev, Naveen, Pickering, Lisa, and Gilbert, Duncan C.

Published
2023
Full Text
View/download PDF

5. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Author

Fendler, Annika, Shepherd, Scott T. C., Au, Lewis, Wilkinson, Katalin A., Wu, Mary, Byrne, Fiona, Cerrone, Maddalena, Schmitt, Andreas M., Joharatnam-Hogan, Nalinie, Shum, Benjamin, Tippu, Zayd, Rzeniewicz, Karolina, Boos, Laura Amanda, Harvey, Ruth, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Sarker, Sarah, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Korteweg, Justine, Foley, Tara, Bazin, Jessica, Gordon, William, Barber, Taja, Emslie-Henry, Andrea, Xie, Wenyi, Gerard, Camille L., Deng, Daqi, Wall, Emma C., Agua-Doce, Ana, Namjou, Sina, Caidan, Simon, Gavrielides, Mike, MacRae, James I., Kelly, Gavin, Peat, Kema, Kelly, Denise, Murra, Aida, Kelly, Kayleigh, O’Flaherty, Molly, Dowdie, Lauren, Ash, Natalie, Gronthoud, Firza, Shea, Robyn L., Gardner, Gail, Murray, Darren, Kinnaird, Fiona, Cui, Wanyuan, Pascual, Javier, Rodney, Simon, Mencel, Justin, Curtis, Olivia, Stephenson, Clemency, Robinson, Anna, Oza, Bhavna, Farag, Sheima, Leslie, Isla, Rogiers, Aljosja, Iyengar, Sunil, Ethell, Mark, Messiou, Christina, Cunningham, David, Chau, Ian, Starling, Naureen, Turner, Nicholas, Welsh, Liam, van As, Nicholas, Jones, Robin L., Droney, Joanne, Banerjee, Susana, Tatham, Kate C., O’Brien, Mary, Harrington, Kevin, Bhide, Shreerang, Okines, Alicia, Reid, Alison, Young, Kate, Furness, Andrew J. S., Pickering, Lisa, Swanton, Charles, Gandhi, Sonia, Gamblin, Steve, Bauer, David L. V., Kassiotis, George, Kumar, Sacheen, Yousaf, Nadia, Jhanji, Shaman, Nicholson, Emma, Howell, Michael, Walker, Susanna, Wilkinson, Robert J., Larkin, James, and Turajlic, Samra

Published
2021
Full Text
View/download PDF

6. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Author

Fendler, Annika, Au, Lewis, Shepherd, Scott T. C., Byrne, Fiona, Cerrone, Maddalena, Boos, Laura Amanda, Rzeniewicz, Karolina, Gordon, William, Shum, Benjamin, Gerard, Camille L., Ward, Barry, Xie, Wenyi, Schmitt, Andreas M., Joharatnam-Hogan, Nalinie, Cornish, Georgina H., Pule, Martin, Mekkaoui, Leila, Ng, Kevin W., Carlyle, Eleanor, Edmonds, Kim, Rosario, Lyra Del, Sarker, Sarah, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Stone, Richard, Gomes, Camila, Flynn, Helen R., Agua-Doce, Ana, Hobson, Philip, Caidan, Simon, Howell, Michael, Wu, Mary, Goldstone, Robert, Crawford, Margaret, Cubitt, Laura, Patel, Harshil, Gavrielides, Mike, Nye, Emma, Snijders, Ambrosius P., MacRae, James I., Nicod, Jerome, Gronthoud, Firza, Shea, Robyn L., Messiou, Christina, Cunningham, David, Chau, Ian, Starling, Naureen, Turner, Nicholas, Welsh, Liam, van As, Nicholas, Jones, Robin L., Droney, Joanne, Banerjee, Susana, Tatham, Kate C., Jhanji, Shaman, O’Brien, Mary, Curtis, Olivia, Harrington, Kevin, Bhide, Shreerang, Bazin, Jessica, Robinson, Anna, Stephenson, Clemency, Slattery, Tim, Khan, Yasir, Tippu, Zayd, Leslie, Isla, Gennatas, Spyridon, Okines, Alicia, Reid, Alison, Young, Kate, Furness, Andrew J. S., Pickering, Lisa, Gandhi, Sonia, Gamblin, Steve, Swanton, Charles, Nicholson, Emma, Kumar, Sacheen, Yousaf, Nadia, Wilkinson, Katalin A., Swerdlow, Anthony, Harvey, Ruth, Kassiotis, George, Larkin, James, Wilkinson, Robert J., and Turajlic, Samra

Published
2021
Full Text
View/download PDF

7. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial

Author

Burn, John, Campbell, Sue, Capaldi, Lisa, Carse, Yvonne, Gadgil, Durga, Goldman, Arnold, Gupta, Sudeep, Leonard, Gregory, MacKenzie, Mairead, Parmar, Mahesh, Patrono, Carlo, Petty, Russell, Rothwell, Peter M., Steele, Robert J.C., Joharatnam-Hogan, Nalinie, Cafferty, Fay, Hubner, Richard, Swinson, Daniel, Sothi, Sharmila, Gupta, Kamalnayan, Falk, Stephen, Patel, Kinnari, Warner, Nicola, Kunene, Victoria, Rowley, Sam, Khabra, Komel, Underwood, Tim, Jankowski, Janusz, Bridgewater, John, Crossley, Anne, Henson, Verity, Berkman, Lindy, Gilbert, Duncan, Kynaston, Howard, Ring, Alistair, Cameron, David, Din, Farhat, Graham, Janet, Iveson, Timothy, Adams, Richard, Thomas, Anne, Wilson, Richard, Pramesh, C S, and Langley, Ruth

Published
2019
Full Text
View/download PDF

8. Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Author

Lee, Rebecca J., Wysocki, Oskar, Zhou, Cong, Shotton, Rohan, Tivey, Ann, Lever, Louise, Woodcock, Joshua, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina E., Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Frost, Hannah, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Huddar, Prerana, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, Mosenthal, Anne C., Obispo, Berta, Patel, Rushin, Pentheroudakis, George, Peters, Solange, Rieger-Christ, Kimberly, Robinson, Timothy, Rogado, Jacobo, Romano, Emanuela, Rowe, Michael, Sekacheva, Marina, Sheehan, Roseleen, Stevenson, Julie, Stockdale, Alexander, Thomas, Anne, Turtle, Lance, Viñal, David, Weaver, Jamie, Williams, Sophie, Wilson, Caroline, Palmieri, Carlo, Landers, Donal, Cooksley, Timothy, Dive, Caroline, Freitas, André, and Armstrong, Anne C.

Published
2022
Full Text
View/download PDF

10. Site staff perspectives on communicating trial results to participants: Cost and feasibility results from the Show RESPECT cluster randomised, factorial, mixed-methods trial

Author

South, Annabelle, primary, Bailey, Julia, additional, Bierer, Barbara E, additional, Burnett, Eva, additional, Cragg, William J, additional, Diaz-Montana, Carlos, additional, Gillies, Katie, additional, Isaacs, Talia, additional, Joharatnam-Hogan, Nalinie, additional, Snowdon, Claire, additional, Sydes, Matthew R, additional, and Copas, Andrew J, additional

Published
2023
Full Text
View/download PDF

12. Testing approaches to sharing trial results with participants: The Show RESPECT cluster randomised, factorial, mixed methods trial

Author

South, Annabelle, Joharatnam-Hogan, Nalinie, Purvis, Cara, James, Elizabeth C., Diaz-Montana, Carlos, Cragg, William J., Tweed, Conor, Macnair, Archie, Sydes, Matthew R., Snowdon, Claire, Gillies, Katie, Isaacs, Talia, Bierer, Barbara E., and Copas, Andrew J.

Subjects
Disclosure of information -- Methods, Clinical trials -- Ethical aspects, Chemotherapy -- Testing, Cancer -- Chemotherapy, Ovarian cancer -- Drug therapy, Biological sciences
Abstract

Background Sharing trial results with participants is an ethical imperative but often does not happen. We tested an Enhanced Webpage versus a Basic Webpage, Mailed Printed Summary versus no Mailed Printed Summary, and Email List Invitation versus no Email List Invitation to see which approach resulted in the highest patient satisfaction with how the results were communicated. Methods and findings We carried out a cluster randomised, 2 by 2 by 2 factorial, nonblinded study within a trial, with semistructured qualitative interviews with some patients (ISRCTN96189403). Each cluster was a UK hospital participating in the ICON8 ovarian cancer trial. Interventions were shared with 384 ICON8 participants who were alive and considered well enough to be contacted, at 43 hospitals. Hospitals were allocated to share results with participants through one of the 8 intervention combinations based on random permutation within blocks of 8, stratified by number of participants. All interventions contained a written plain English summary of the results. The Enhanced Webpage also contained a short video. Both the Enhanced Webpage and Email contained links to further information and support. The Mailed Printed Summary was opt-out. Follow-up questionnaires were sent 1 month after patients had been offered the interventions. Patients' reported satisfaction was measured using a 5-point scale, analysed by ordinal logistic regression estimating main effects for all 3 interventions, with random effects for site, restricted to those who reported receiving the results and assuming no interaction. Data collection took place in 2018 to 2019. Questionnaires were sent to 275/384 randomly selected participants and returned by 180: 90/142 allocated Basic Webpage, 90/133 Enhanced Webpage; 91/141 no Mailed Printed Summary, 89/134 Mailed Printed Summary; 82/129 no Email List Invitation, 98/146 Email List Invitation. Only 3 patients opted out of receiving the Mailed Printed Summary; no patients signed up to the email list. Patients' satisfaction was greater at sites allocated the Mailed Printed Summary, where 65/81 (80%) were quite or very satisfied compared to sites with no Mailed Printed Summary 39/64 (61%), ordinal odds ratio (OR) = 3.15 (1.66 to 5.98, p < 0.001). We found no effect on patient satisfaction from the Enhanced Webpage, OR = 1.47 (0.78 to 2.76, p = 0.235) or Email List Invitation, OR = 1.38 (0.72 to 2.63, p = 0.327). Interviewees described the results as interesting, important, and disappointing (the ICON8 trial found no benefit). Finding out the results made some feel their trial participation had been more worthwhile. Regardless of allocated group, patients who received results generally reported that the information was easy to understand and find, were glad and did not regret finding out the results. The main limitation of our study is the 65% response rate. Conclusions Nearly all respondents wanted to know the results and were glad to receive them. Adding an opt-out Mailed Printed Summary alongside a webpage yielded the highest reported satisfaction. This study provides evidence on how to share results with other similar trial populations. Further research is needed to look at different results scenarios and patient populations. Trial registration ISRCTN: ISRCTN96189403., Author(s): Annabelle South 1,*, Nalinie Joharatnam-Hogan 1, Cara Purvis 1, Elizabeth C. James 1, Carlos Diaz-Montana 1, William J. Cragg 2, Conor Tweed 1, Archie Macnair 1, Matthew R. Sydes [...]

Published
2021
Full Text
View/download PDF

14. An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

Author

Wysocki, Oskar, Zhou, Cong, Rogado, Jacobo, Huddar, Prerana, Shotton, Rohan, Tivey, Ann, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina, Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Lewis, Alexandra, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, Mosenthal, Anne C., Wysocki, Oskar, Zhou, Cong, Rogado, Jacobo, Huddar, Prerana, Shotton, Rohan, Tivey, Ann, Albiges, Laurence, Angelakas, Angelos, Arnold, Dirk, Aung, Theingi, Banfill, Kathryn, Baxter, Mark, Barlesi, Fabrice, Bayle, Arnaud, Besse, Benjamin, Bhogal, Talvinder, Boyce, Hayley, Britton, Fiona, Calles, Antonio, Castelo-Branco, Luis, Copson, Ellen, Croitoru, Adina, Dani, Sourbha S., Dickens, Elena, Eastlake, Leonie, Fitzpatrick, Paul, Foulon, Stephanie, Frederiksen, Henrik, Ganatra, Sarju, Gennatas, Spyridon, Glenthøj, Andreas, Gomes, Fabio, Graham, Donna M., Hague, Christina, Harrington, Kevin, Harrison, Michelle, Horsley, Laura, Hoskins, Richard, Hudson, Zoe, Jakobsen, Lasse H., Joharatnam-Hogan, Nalinie, Khan, Sam, Khan, Umair T., Khan, Khurum, Lewis, Alexandra, Massard, Christophe, Maynard, Alec, McKenzie, Hayley, Michielin, Olivier, and Mosenthal, Anne C.

Abstract

Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely severity of COVID-19 in patients with active cancer who present to hospital. We assessed the differences in presentation and outcomes of patients with cancer and COVID-19, depending on the wave of the pandemic. We examined differences in features at presentation and outcomes in patients worldwide, depending on the waves of the pandemic: wave 1 D614G (n = 1430), wave 2 Alpha (n = 475), and wave 4 Omicron variant (n = 63, UK and Spain only). The performance of CORONET was evaluated on 258, 48, and 54 patients for each wave, respectively. We found that mortality rates were reduced in subsequent waves. The majority of patients were vaccinated in wave 4, and 94% were treated with steroids if they required oxygen. The stages of cancer and the median ages of patients significantly differed, but features associated with worse COVID-19 outcomes remained predictive and did not differ between waves. The CORONET tool performed well in all waves, with scores in an area under the curve (AUC) of >0.72. We concluded that patients with cancer who present to hospital with COVID-19 have similar features of severity, which remain discriminatory despite differences in variants and vaccination status. Survival improved following the first wave of the pandemic, which may be associated with vaccination and the increased steroid use in those patients requiring oxygen. The CORONET model demonstrated good performance, independent of the SARS-CoV-2 variants.

Published
2022

15. Diabetes and cancer: Optimising glycaemic control.

Author

Joharatnam‐Hogan, Nalinie and Morganstein, Daniel L.

Subjects
*TUMOR risk factors, *TUMOR treatment, *HYPERGLYCEMIA prevention, *PANCREATIC tumors, *HYPERGLYCEMIA, *ADRENOCORTICAL hormones, *GLYCEMIC control, *ANTINEOPLASTIC agents, *TYPE 2 diabetes, *PROTEIN-tyrosine kinase inhibitors, *PANCREATECTOMY, *TUMORS, *CANCER patient medical care, *IMMUNOTHERAPY, *DISEASE risk factors, *DISEASE complications
Abstract

Diabetes and cancer are both common and increasingly prevalent conditions, but emerging epidemiological evidence confirms that the risk of developing a number of common cancers is increased in those with type 2 diabetes. The risk of cancer in type 1 diabetes is less clearly defined, and therefore this review focuses on type 2 diabetes. Emerging evidence also supports an influence of diabetes on outcomes of cancer treatment. However, this relationship is bi‐directional, with cancer and its treatment impacting on glucose control, whereas there is also emerging evidence indicating that diabetes care can deteriorate after a cancer diagnosis. Despite these clear links, there is a lack of evidence to guide clinicians in how to manage patients with diabetes during their cancer treatment. Although recent UK guidelines have started to address this, with the development of guidance for the management of hyperglycaemia in cancer, there is a clear need for wider guidance on the management of multi‐morbidity during cancer, including diabetes and obesity, to incorporate nutritional management. We have therefore undertaken a narrative review of the evidence of links between type 2 diabetes and cancer incidence and outcomes, and discuss the challenges to diabetes care during cancer treatment. Key points: Diabetes and cancer frequently occur together multiple solid and haematological cancers occur at increased frequency in those with type 2 diabetes multiple cancer treatments can cause hyperglycaemia or worsen control in those with diabetes. Newer targeted treatments, especially mammalian target of rapamycin and phosphoinositide 3‐kinase inhibitors, are likely to cause hyperglycaemia diabetes may also worsen cancer outcomes [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

Author

Fendler, Annika, Shepherd, Scott TC, Au, Lewis, Wilkinson, Katalin A, Wu, Mary, Byrne, Fiona, Cerrone, Maddalena, Schmitt, Andreas M, Joharatnam-Hogan, Nalinie, Shum, Benjamin, Tippu, Zayd, Rzeniewicz, Karolina, Boos, Laura Amanda, Harvey, Ruth, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Sarker, Sarah, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Korteweg, Justine, Foley, Tara, Bazin, Jessica, Gordon, William, Barber, Taja, Emslie-Henry, Andrea, Xie, Wenyi, Gerard, Camille L, Deng, Daqi, Wall, Emma C, Agua-Doce, Ana, Namjou, Sina, Caidan, Simon, Gavrielides, Mike, MacRae, James I, Kelly, Gavin, Peat, Kema, Kelly, Denise, Murra, Aida, Kelly, Kayleigh, O���Flaherty, Molly, Dowdie, Lauren, Ash, Natalie, Gronthoud, Firza, Shea, Robyn L, Gardner, Gail, Murray, Darren, Kinnaird, Fiona, Cui, Wanyuan, Pascual, Javier, Rodney, Simon, Mencel, Justin, Curtis, Olivia, Stephenson, Clemency, Robinson, Anna, Oza, Bhavna, Farag, Sheima, Leslie, Isla, Rogiers, Aljosja, Iyengar, Sunil, Ethell, Mark, Messiou, Christina, Cunningham, David, Chau, Ian, Starling, Naureen, Turner, Nicholas, Welsh, Liam, van As, Nicholas, Jones, Robin L, Droney, Joanne, Banerjee, Susana, Tatham, Kate C, O���Brien, Mary, Harrington, Kevin, Bhide, Shreerang, Okines, Alicia, Reid, Alison, Young, Kate, Furness, Andrew JS, Pickering, Lisa, Swanton, Charles, Consortium, The Crick COVID-19, Gandhi, Sonia, Gamblin, Steve, Bauer, David LV, Kassiotis, George, Kumar, Sacheen, Yousaf, Nadia, Jhanji, Shaman, Nicholson, Emma, Howell, Michael, Walker, Susanna, Wilkinson, Robert J, Larkin, James, Turajlic, Samra, and Consortium, The CAPTURE

Subjects
Model organisms, Chemical Biology & High Throughput, Human Biology & Physiology, FOS: Clinical medicine, Stem Cells, Genome Integrity & Repair, Immunology, Neurosciences, Infectious Disease, Cell Biology, Tumour Biology, Biochemistry & Proteomics, Signalling & Oncogenes, Metabolism, Ecology,Evolution & Ethology, Cell Cycle & Chromosomes, Genetics & Genomics, Developmental Biology, Structural Biology & Biophysics, Computational & Systems Biology
Abstract

Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were 85% and 59% in patients with solid and hematological malignancies, respectively. A lower proportion of patients had detectable titers of neutralizing antibodies (NAbT) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOC) versus wild-type (WT) SARS-CoV-2. Patients with hematological malignancies were more likely to have undetectable NAbT and had lower median NAbT than those with solid cancers against both SARS-CoV-2 WT and VOC. By comparison with individuals without cancer, patients with hematological, but not solid, malignancies had reduced neutralizing antibody (NAb) responses. Seroconversion showed poor concordance with NAbT against VOC. Previous SARS-CoV-2 infection boosted the NAb response including against VOC, and anti-CD20 treatment was associated with undetectable NAbT. Vaccine-induced T cell responses were detected in 80% of patients and were comparable between vaccines or cancer types. Our results have implications for the management of patients with cancer during the ongoing COVID-19 pandemic.

Published
2022
Full Text
View/download PDF

17. Supplementary_Appendix_Final – Supplemental material for Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience

Author

Joharatnam-Hogan, Nalinie, Hochhauser, Daniel, Shiu, Kai-Keen, Rush, Hannah, Crolley, Valerie, Wilson, William, Sharma, Anand, Muhammad, Aun, Anwar, Muhammad, Vasdev, Nikhil, Goldstein, Robert, Kantser, Ganna, Saha, Aramita, Raja, Fharat, Bridgewater, John, and Khan, Khurum

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, Supplementary_Appendix_Final for Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience by Nalinie Joharatnam-Hogan, Daniel Hochhauser, Kai-Keen Shiu, Hannah Rush, Valerie Crolley, William Wilson, Anand Sharma, Aun Muhammad, Muhammad Anwar, Nikhil Vasdev, Robert Goldstein, Ganna Kantser, Aramita Saha, Fharat Raja, John Bridgewater and Khurum Khan in Therapeutic Advances in Medical Oncology

Published
2022
Full Text
View/download PDF

18. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Author

Fendler, Annika, Au, Lewis, Shepherd, Scott TC, Byrne, Fiona, Cerrone, Maddalena, Boos, Laura Amanda, Rzeniewicz, Karolina, Gordon, William, Shum, Benjamin, Gerard, Camille L, Ward, Barry, Xie, Wenyi, Schmitt, Andreas M, Joharatnam-Hogan, Nalinie, Cornish, Georgina H, Pule, Martin, Mekkaoui, Leila, Ng, Kevin W, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Sarker, Sarah, Lingard, Karla, Mangwende, Mary, Holt, Lucy, Ahmod, Hamid, Stone, Richard, Gomes, Camila, Flynn, Helen R, Agua-Doce, Ana, Hobson, Philip, Caidan, Simon, Howell, Michael, Wu, Mary, Goldstone, Robert, Crawford, Margaret, Cubitt, Laura, Patel, Harshil, Gavrielides, Mike, Nye, Emma, Snijders, Ambrosius P, MacRae, James I, Nicod, Jerome, Gronthoud, Firza, Shea, Robyn L, Messiou, Christina, Cunningham, David, Chau, Ian, Starling, Naureen, Turner, Nicholas, Welsh, Liam, van As, Nicholas, Jones, Robin L, Droney, Joanne, Banerjee, Susana, Tatham, Kate C, Jhanji, Shaman, O���Brien, Mary, Curtis, Olivia, Harrington, Kevin, Bhide, Shreerang, Bazin, Jessica, Robinson, Anna, Stephenson, Clemency, Slattery, Tim, Khan, Yasir, Tippu, Zayd, Leslie, Isla, Gennatas, Spyridon, Okines, Alicia, Reid, Alison, Young, Kate, Furness, Andrew JS, Pickering, Lisa, Gandhi, Sonia, Gamblin, Steve, Swanton, Charles, Consortium, The Crick COVID-19, Nicholson, Emma, Kumar, Sacheen, Yousaf, Nadia, Wilkinson, Katalin A, Swerdlow, Anthony, Harvey, Ruth, Kassiotis, George, Larkin, James, Wilkinson, Robert J, Turajlic, Samra, and consortium, The CAPTURE

Subjects
Model organisms, Chemical Biology & High Throughput, Human Biology & Physiology, FOS: Clinical medicine, Stem Cells, Genome Integrity & Repair, Immunology, Neurosciences, Infectious Disease, Cell Biology, Tumour Biology, Biochemistry & Proteomics, Signalling & Oncogenes, Metabolism, Ecology,Evolution & Ethology, Cell Cycle & Chromosomes, Genetics & Genomics, Developmental Biology, Structural Biology & Biophysics, Computational & Systems Biology
Abstract

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.

Published
2022
Full Text
View/download PDF

19. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

Author

Fendler, Annika, primary, Shepherd, Scott, additional, Au, Lewis, additional, Wilkinson, Katalin, additional, Wu, Mary, additional, Byrne, Fiona, additional, Cerrone, Maddalena, additional, Schmitt, Andreas, additional, Joharatnam-Hogan, Nalinie, additional, Shum, Ben, additional, Tippu, Zayd, additional, Rzeniewicz, Karolina, additional, Boos, Laura, additional, Harvey, Ruth, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Rosario, Lyra Del, additional, Sarker, Sarah, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Koreweg, Justine, additional, Foley, Tara, additional, Bazin, Jessica, additional, Gordon, William, additional, Barber, Taja, additional, Emslie-Henry, Andrea, additional, Xie, Wenyi, additional, Gerard, Camille, additional, Deng, Daqi, additional, Wall, Emma, additional, Agua-Doce, Ana, additional, Namjou, Sina, additional, Caidan, Simon, additional, Gavrielides, Mike, additional, MacRae, James, additional, Kelly, Gavin, additional, Peat, Kema, additional, Kelly, Denise, additional, Murra, Aida, additional, Kelly, Kayleigh, additional, O'Flaherty, Molly, additional, Dowdie, Lauren, additional, Ash, Natalie, additional, Grounthoud, Firza, additional, Shea, Robyn, additional, Gardner, Gail, additional, Murray, Darren, additional, Kinnaird, Fiona, additional, Cui, Wanyuan, additional, Pascual, Javier, additional, Rodney, Simon, additional, Mencel, Justin, additional, Curtis, Olivia, additional, Stephenson, Clemency, additional, Robinson, Anna, additional, Oza, Bhavna, additional, Farag, Sheima, additional, Leslie, Isla, additional, Rogiers, Aljosja, additional, Lyengar, Sunil, additional, Ethell, Mark, additional, Messiou, Christina, additional, Cunningham, David, additional, Chau, Ian, additional, Starling, Naureen, additional, Turner, Nicholas, additional, Welsh, Liam, additional, As, Nicholas van, additional, Jones, Robin, additional, DRoney, Joanne, additional, Banerjee, Susana, additional, Tatham, Kate, additional, O'Brien, Mary, additional, Harrington, Kevin, additional, Bhide, Shreerang, additional, Okines, Alicia, additional, Reid, Alison, additional, Young, Kate, additional, Furness, Andrew, additional, Pickering, Lisa, additional, Swanton, Charles, additional, Gandhi, Sonia, additional, Gamblin, Steve, additional, Bauer, David, additional, Kassiotis, George, additional, Kumar, Sacheen, additional, Yousaf, Nadia, additional, Jhanji, Shaman, additional, Nicholson, Emma, additional, Howell, Michael, additional, Walker, Susanna, additional, Wilkinson, Robert, additional, Larkin, James, additional, and Turajlic, Samra, additional

Published
2021
Full Text
View/download PDF

20. Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Author

Fendler, Annika, primary, Au, Lewis, additional, Shepherd, Scott, additional, Byrne, Fiona, additional, Cerrone, Maddalena, additional, Boos, Laura, additional, Rzeniewicz, Karolina, additional, Gordon, William, additional, Shum, Ben, additional, Gerard, Camille, additional, Ward, Barry, additional, Xie, Wenyi, additional, Schmitt, Andreas, additional, Joharatnam-Hogan, Nalinie, additional, Cornish, Georgina, additional, Pule, Martin, additional, Mekkaoui, Leila, additional, Ng, Kevin, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Rosario, Lyra Del, additional, Sarker, Sarah, additional, Lingard, Karla, additional, Mangwende, Mary, additional, Holt, Lucy, additional, Ahmod, Hamid, additional, Stone, Richard, additional, Gomes, Camila, additional, Flynn, Helen, additional, Agua-Doce, Ana, additional, Hobson, Philip, additional, Caidan, Simon, additional, Howell, Michael, additional, Wu, Mary, additional, Goldstone, Robert, additional, Crawford, Margaret, additional, Cubitt, Laura, additional, Patel, Harshil, additional, Gavrielides, Mike, additional, Nye, Emma, additional, Snijders, Ambrosius, additional, MacRae, James, additional, Nicod, Jerome, additional, Gronthoud, Firza, additional, Shea, Robyn, additional, Messiou, Christina, additional, Cunningham, David, additional, Chau, Ian, additional, Starling, Naureen, additional, Turner, Nicholas, additional, Welsh, Liam, additional, As, Nicholas van, additional, Jones, Robin, additional, Droney, Joanne, additional, Banerjee, Susana, additional, Tatham, Kate, additional, Jhanji, Shaman, additional, O'Brien, Mary, additional, Curtis, Oliva, additional, Harrington, Kevin, additional, Bhide, Shreerang, additional, Bazin, Jessica, additional, Robinson, Anna, additional, Stephenson, Clemency, additional, Slattery, Tim, additional, Khan, Yasir, additional, Tippu, Zayd, additional, Leslie, Isla, additional, Gennatas, Spyridon, additional, Okines, Alicia, additional, Reid, Alison, additional, Young, Kate, additional, Furness, Andrew, additional, Pickering, Lisa, additional, Gandhi, Sonia, additional, Gamblin, Steve, additional, Swanton, Charles, additional, Nicholson, Emma, additional, Kumar, Sacheen, additional, Yousaf, Nadia, additional, Wilkinson, Katalin, additional, Swerdlow, Anthony, additional, Harvey, Ruth, additional, Kassiotis, George, additional, Larkin, James, additional, Wilkinson, Robert, additional, and Turajlic, Samra, additional

Published
2021
Full Text
View/download PDF

21. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2

Author

Au, Lewis, Fendler, Annika, Shepherd, Scott TC, Rzeniewicz, Karolina, Cerrone, Maddalena, Byrne, Fiona, Carlyle, Eleanor, Edmonds, Kim, Del Rosario, Lyra, Shon, John, Haynes, Winston A, Ward, Barry, Shum, Ben, Gordon, William, Gerard, Camille L, Xie, Wenyi, Joharatnam-Hogan, Nalinie, Young, Kate, Pickering, Lisa, Furness, Andrew JS, Larkin, James, Harvey, Ruth, Kassiotis, George, Gandhi, Sonia, Consortium, Crick COVID-19, Swanton, Charles, Fribbens, Charlotte, Wilkinson, Katalin A, Wilkinson, Robert J, Lau, David K, Banerjee, Susana, Starling, Naureen, Chau, Ian, Consortium, CAPTURE, and Turajlic, Samra

Subjects
Model organisms, Chemical Biology & High Throughput, Human Biology & Physiology, FOS: Clinical medicine, Stem Cells, Genome Integrity & Repair, Immunology, Neurosciences, Infectious Disease, Cell Biology, Tumour Biology, Signalling & Oncogenes, Ecology,Evolution & Ethology, Genetics & Genomics, Computational & Systems Biology
Abstract

Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population.

Published
2021
Full Text
View/download PDF

22. Outcomes for cancer patients on systemic anti-cancer therapies during the COVID-19 pandemic from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.

Author

Crolley, Valerie, primary, Hanna, Daire, additional, Joharatnam-Hogan, Nalinie, additional, Chopra, Neha, additional, Bamac, Ekin, additional, Desai, Meera, additional, Lam, Yuk-Chun, additional, Dipro, Sabiq, additional, Kanani, Ruhi, additional, Benson, Jack, additional, Wilson, William, additional, Fox, Thomas Andrew, additional, Shiu, Kai-Keen, additional, Forster, Martin, additional, Bridgewater, John A., additional, Hochhauser, Daniel, additional, and Khan, Khurum Hayat, additional

Published
2021
Full Text
View/download PDF

24. Cytokine release syndrome in a patient with colorectal cancer following vaccination with BNT162b2 (tozinameran)

Author

Turajlic, Samra, primary, Au, Lewis, additional, Fendler, Annika, additional, Shepherd, Scott, additional, Rzeniewicz, Karolina, additional, Cerrone, Maddalena, additional, Byrne, Fiona, additional, Carlyle, Eleanor, additional, Edmonds, Kim, additional, Rosario, Lyra Del, additional, Shon, John, additional, Haynes, Winston, additional, Ward, Barry, additional, Shum, Ben, additional, Gordon, William, additional, Gerard, Camille, additional, Xie, Wenyi, additional, Joharatnam-Hogan, Nalinie, additional, Young, Kate, additional, Furness, Andrew, additional, Pickering, Lisa, additional, Larkin, James, additional, Harvey, Ruth, additional, Kassiotis, George, additional, Gandhi, Sonia, additional, Swanton, Charles, additional, Fribbens, Charlotte, additional, Wilkinson, Katalin, additional, Wilkinson, Robert, additional, Lau, David, additional, Starling, Naureen, additional, and Chau, Ian, additional

Published
2021
Full Text
View/download PDF

25. Establishment of CORONET: COVID-19 Risk in Oncology Evaluation Tool to Identify Cancer Patients at Low Versus High Risk of Severe Complications of COVID-19 Infection Upon Presentation to Hospital

Author

Lee, Rebecca, primary, Wysocki, Oskar, additional, Zhou, C., additional, Shotton, Rohan, additional, Tivey, Ann, additional, Lever, Louise, additional, Woodcock, Joshua, additional, Angelakas, Angelos, additional, Arnold, D., additional, Aung, Theingi, additional, Banfill, Kathryn, additional, Baxter, Mark, additional, Bhogal, Talvinder, additional, Boyce, Hayley, additional, Britton, Fiona, additional, Calles, Antonio, additional, Castelo-Branco, Louis, additional, Copson, Ellen, additional, Croitoru, Adina, additional, Dani, Sourbha, additional, Dickens, Elena, additional, Eastlake, Leonie, additional, Fitzpatrick, P., additional, Frost, H., additional, Ganatra, Sarju, additional, Gennatas, Spyridon, additional, Gomes, F., additional, Graham, Donna, additional, Hague, Christina, additional, Harrington, Kevin, additional, Harrison, Michelle, additional, Horsley, Laura, additional, Hoskins, R., additional, Huddar, Prerana, additional, Hudson, Zoe, additional, Joharatnam-Hogan, Nalinie, additional, Khan, S., additional, Khan, U.T., additional, Khan, Khurum, additional, Maynard, Alec, additional, McKenzie, H., additional, Michielin, Olivier, additional, Mosenthal, Anne, additional, Obispo, Berta, additional, Patel, Rushin, additional, pentheroudakis, George, additional, peters, solange, additional, Rieger-Christ, Kimberly, additional, Robinson, T., additional, Rogado, Jacobo, additional, Romano, Emanuela, additional, Rowe, M., additional, Sekacheva, Marina, additional, Sheehan, Roseleen, additional, Stevenson, Julie, additional, Stockdale, Alexander J., additional, Thomas, A., additional, Turtle, Lance, additional, Viñal, D., additional, Weaver, J., additional, Williams, S., additional, Wilson, C., additional, Palmieri, Carlo, additional, Landers, Donal, additional, Cooksley, Tim, additional, Group, ESMO Co-Care, additional, Dive, Caroline, additional, Freitas, Andre, additional, and Armstrong, A. C., additional

Published
2021
Full Text
View/download PDF

27. Outcomes of the 2019 Novel Coronavirus in patients with or without a history of cancer - a multi-centre North London experience

Author

Joharatnam-Hogan, Nalinie, primary, Hochhauser, Daniel, additional, Shiu, Kai-Keen, additional, Rush, Hannah, additional, Crolley, Valerie, additional, Butcher, Emma, additional, Sharma, Anand, additional, Muhammad, Aun, additional, Anwar, Muhammad, additional, Vasdev, Nikhil, additional, Kantser, Ganna, additional, Saha, Aramita, additional, Raja, Fharat, additional, Bridgewater, John, additional, and Khan, Khurum, additional

Published
2020
Full Text
View/download PDF

30. COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study

Author

Crolley, Valerie E., primary, Hanna, Daire, additional, Joharatnam-Hogan, Nalinie, additional, Chopra, Neha, additional, Bamac, Ekin, additional, Desai, Meera, additional, Lam, Yuk-Chun, additional, Dipro, Sabiq, additional, Kanani, Ruhi, additional, Benson, Jack, additional, Wilson, William, additional, Fox, Thomas A., additional, Shiu, Kai-Keen, additional, Forster, Martin, additional, Bridgewater, John, additional, Hochhauser, Daniel, additional, and Khan, Khurum, additional

Published
2020
Full Text
View/download PDF

31. COVID-19 in Cancer Patients on Systemic Anti-Cancer Therapies – Outcomes from CAPITOL (COVID-19 Cancer PatIenTOutcomes in North London)

Author

Crolley, Valerie E., primary, Hanna, Daire, additional, Joharatnam-Hogan, Nalinie, additional, Chopra, Neha, additional, Bamac, Ekin, additional, Desai, Meera, additional, Lam, Yuk-Chun, additional, Dipro, Sabiq, additional, Kanani, Ruhi, additional, Benson, Jack, additional, Wilson, William, additional, Fox, Thomas A., additional, Shiu, Kai-Keen, additional, Forster, Martin, additional, Bridgewater, John, additional, Hochhauser, Daniel, additional, and Khan, Khurum, additional

Published
2020
Full Text
View/download PDF

32. A guideline for the outpatient management of glycaemic control in people with cancer.

Author

Joharatnam‐Hogan, Nalinie, Chambers, Pinkie, Dhatariya, Ketan, and Board, Ruth

Subjects
*DIABETES risk factors, *THERAPEUTIC use of antineoplastic agents, *HYPERGLYCEMIA, *GLYCEMIC control, *HEMATOLOGY, *DIABETES, *MEDICAL protocols, *CANCER patients, *RISK assessment, *HEALTH care teams, *TUMORS, *OUTPATIENT services in hospitals, *DISEASE management, *ONCOLOGY, *DISEASE risk factors, *DISEASE complications, THERAPEUTIC use of glucocorticoids
Abstract

Individuals with cancer are at increased risk of developing new‐onset diabetes mellitus and hyperglycaemia, and an estimated 20% of people with cancer already have an underlying diagnosis of diabetes mellitus. People with both cancer and diabetes may have an increased risk of toxicities, hospital admissions and morbidity, with hyperglycaemia potentially attenuating the efficacy of chemotherapy often secondary to dose reductions and early cessation. Numerous studies have demonstrated that hyperglycaemia is prognostic of worse overall survival and risk of cancer recurrence. These guidelines aim to provide the oncology/haemato‐oncology and diabetes multidisciplinary teams with the tools to manage people with diabetes commencing anti‐cancer/glucocorticoid therapy, as well as identifying individuals without a known diagnosis of diabetes who are at risk of developing hyperglycaemia and new‐onset diabetes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial

Author

Joharatnam-Hogan, Nalinie, primary, Cafferty, Fay, additional, Hubner, Richard, additional, Swinson, Daniel, additional, Sothi, Sharmila, additional, Gupta, Kamalnayan, additional, Falk, Stephen, additional, Patel, Kinnari, additional, Warner, Nicola, additional, Kunene, Victoria, additional, Rowley, Sam, additional, Khabra, Komel, additional, Underwood, Tim, additional, Jankowski, Janusz, additional, Bridgewater, John, additional, Crossley, Anne, additional, Henson, Verity, additional, Berkman, Lindy, additional, Gilbert, Duncan, additional, Kynaston, Howard, additional, Ring, Alistair, additional, Cameron, David, additional, Din, Farhat, additional, Graham, Janet, additional, Iveson, Timothy, additional, Adams, Richard, additional, Thomas, Anne, additional, Wilson, Richard, additional, Pramesh, C S, additional, Langley, Ruth, additional, Burn, John, additional, Campbell, Sue, additional, Capaldi, Lisa, additional, Carse, Yvonne, additional, Gadgil, Durga, additional, Goldman, Arnold, additional, Gupta, Sudeep, additional, Leonard, Gregory, additional, MacKenzie, Mairead, additional, Parmar, Mahesh, additional, Patrono, Carlo, additional, Petty, Russell, additional, Rothwell, Peter M., additional, and Steele, Robert J.C., additional

Published
2019
Full Text
View/download PDF

34. Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience.

Author

Joharatnam-Hogan, Nalinie, Hochhauser, Daniel, Shiu, Kai-Keen, Rush, Hannah, Crolley, Valerie, Wilson, William, Sharma, Anand, Muhammad, Aun, Anwar, Muhammad, Vasdev, Nikhil, Goldstein, Robert, Kantser, Ganna, Saha, Aramita, Raja, Fharat, Bridgewater, John, and Khan, Khurum

Abstract

Background: This study aims to compare the outcomes of COVID-19-positive disease in patients with a history of cancer to those without. Methods: We retrospectively collected clinical data and outcomes of COVID-19 positive cancer patients treated consecutively in five North London hospitals (cohort A). Outcomes recorded included time interval between most recent anti-cancer treatment and admission, severe outcome [a composite endpoint of intensive care unit (ITU) admission, ventilation and/or death] and mortality. Outcomes were compared with consecutively admitted COVID-19 positive patients, without a history of cancer (cohort B), treated at the primary centre during the same time period (1 March–30 April 2020). Patients were matched for age, gender and comorbidity. Results: The median age in both cohorts was 74 years, with 67% male, and comprised of 30 patients with cancer, and 90 without (1:3 ratio). For cohort B, 579 patients without a history of cancer and consecutively admitted were screened from the primary London hospital, 105 were COVID-19 positive and 90 were matched and included. Excluding cancer, both cohorts had a median of two comorbidities. The odds ratio (OR) for mortality, comparing patients with cancer to those without, was 1.05 [95% confidence interval (CI) 0.4–2.5], and severe outcome (OR 0.89, 95% CI 0.4–2.0) suggesting no increased risk of death or a severe outcome in patients with cancer. Cancer patients who received systemic treatment within 28 days had an OR for mortality of 4.05 (95% CI 0.68–23.95), p = 0.12. On presentation anaemia, hypokalaemia, hypoalbuminaemia and hypoproteinaemia were identified predominantly in cohort A. Median duration of admission was 8 days for cancer patients and 7 days for non-cancer. Conclusion: A diagnosis of cancer does not appear to increase the risk of death or a severe outcome in COVID-19 patients with cancer compared with those without cancer. If a second spike of virus strikes, rational decision making is required to ensure optimal cancer care. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

35. An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.

Author

Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, Foulon S, Frederiksen H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Lewis A, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Palmieri C, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Romano E, Rowe M, Sekacheva M, Sheehan R, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Dive C, Landers D, Cooksley T, Freitas A, Armstrong AC, Lee RJ, and On Behalf Of The Esmo Co-Care

Abstract

Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely severity of COVID-19 in patients with active cancer who present to hospital. We assessed the differences in presentation and outcomes of patients with cancer and COVID-19, depending on the wave of the pandemic. We examined differences in features at presentation and outcomes in patients worldwide, depending on the waves of the pandemic: wave 1 D614G (n = 1430), wave 2 Alpha (n = 475), and wave 4 Omicron variant (n = 63, UK and Spain only). The performance of CORONET was evaluated on 258, 48, and 54 patients for each wave, respectively. We found that mortality rates were reduced in subsequent waves. The majority of patients were vaccinated in wave 4, and 94% were treated with steroids if they required oxygen. The stages of cancer and the median ages of patients significantly differed, but features associated with worse COVID-19 outcomes remained predictive and did not differ between waves. The CORONET tool performed well in all waves, with scores in an area under the curve (AUC) of >0.72. We concluded that patients with cancer who present to hospital with COVID-19 have similar features of severity, which remain discriminatory despite differences in variants and vaccination status. Survival improved following the first wave of the pandemic, which may be associated with vaccination and the increased steroid use in those patients requiring oxygen. The CORONET model demonstrated good performance, independent of the SARS-CoV-2 variants.

Published
2022
Full Text
View/download PDF

36. Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Author

Fendler A, Au L, Shepherd STC, Byrne F, Cerrone M, Boos LA, Rzeniewicz K, Gordon W, Shum B, Gerard CL, Ward B, Xie W, Schmitt AM, Joharatnam-Hogan N, Cornish GH, Pule M, Mekkaoui L, Ng KW, Carlyle E, Edmonds K, Del Rosario L, Sarker S, Lingard K, Mangwende M, Holt L, Ahmod H, Stone R, Gomes C, Flynn HR, Agua-Doce A, Hobson P, Caidan S, Howell M, Wu M, Goldstone R, Crawford M, Cubitt L, Patel H, Gavrielides M, Nye E, Snijders AP, MacRae JI, Nicod J, Gronthoud F, Shea RL, Messiou C, Cunningham D, Chau I, Starling N, Turner N, Welsh L, van As N, Jones RL, Droney J, Banerjee S, Tatham KC, Jhanji S, O'Brien M, Curtis O, Harrington K, Bhide S, Bazin J, Robinson A, Stephenson C, Slattery T, Khan Y, Tippu Z, Leslie I, Gennatas S, Okines A, Reid A, Young K, Furness AJS, Pickering L, Gandhi S, Gamblin S, Swanton C, Nicholson E, Kumar S, Yousaf N, Wilkinson KA, Swerdlow A, Harvey R, Kassiotis G, Larkin J, Wilkinson RJ, and Turajlic S

Abstract

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2-positive, 94 were symptomatic and 2 patients died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies, 82% had neutralizing antibodies against WT, whereas neutralizing antibody titers (NAbT) against the Alpha, Beta, and Delta variants were substantially reduced. Whereas S1-reactive antibody levels decreased in 13% of patients, NAbT remained stable up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment-specific, but presented compensatory cellular responses, further supported by clinical. Overall, these findings advance the understanding of the nature and duration of immune response to SARS-CoV-2 in patients with cancer.

Published
2021
Full Text
View/download PDF

37. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.

Author

Au L, Fendler A, Shepherd STC, Rzeniewicz K, Cerrone M, Byrne F, Carlyle E, Edmonds K, Del Rosario L, Shon J, Haynes WA, Ward B, Shum B, Gordon W, Gerard CL, Xie W, Joharatnam-Hogan N, Young K, Pickering L, Furness AJS, Larkin J, Harvey R, Kassiotis G, Gandhi S, Swanton C, Fribbens C, Wilkinson KA, Wilkinson RJ, Lau DK, Banerjee S, Starling N, Chau I, and Turajlic S

Subjects
COVID-19 metabolism, COVID-19 prevention & control, Humans, Male, SARS-CoV-2 isolation & purification, COVID-19 Vaccines adverse effects, Colorectal Neoplasms metabolism, Cytokine Release Syndrome
Abstract

Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

38. Diabetes Mellitus in People with Cancer

Author

Joharatnam-Hogan N, Carter TJ, Reynolds N, Ho JH, Adam S, Board R, Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, and Wilson DP

Abstract

There is increasing evidence of an association between cancer and diabetes mellitus. Patients with type II diabetes are at increased risk of malignancy due to shared risk factors between the two conditions, and people with a diagnosis of cancer may develop new onset diabetes or impaired glycemic control, partly as a result of the systemic anti-cancer treatments (SACT) they receive. Many newer targeted anti-cancer treatments can have off-target metabolic toxicities not seen with conventional chemotherapy agents. Early recognition of diabetes or hyperglycemia in people with cancer can improve outcomes. This chapter aims to summarize these associations, provide an overview of how different SACT modalities can impact on glycemic control, and highlight key recommendations for the management of this complex patient group. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG., (Copyright © 2000-2022, MDText.com, Inc.)

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results